IGM Biosciences to cut 73% of workforce
Royal Bank of Canada lowered shares of IGM Biosciences (NASDAQ:IGMS – Free Report) from an outperform rating to a sector ...
IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...
Hosted on MSN2d
Stifel Downgrades IGM Biosciences (IGMS)Fintel reports that on January 10, 2025, Stifel downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to Hold ...
IGM Biosciences (NASDAQ:IGMS – Get Free Report) had its target price reduced by research analysts at Truist Financial from ...
Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company ...
Truist analyst Asthika Goonewardene lowered the firm’s price target on IGM Biosciences (IGMS) to $2 from $12 and keeps a Hold rating on the ...
Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...
IGM Biosciences (IGMS) stock faces sharp selloff as the company abandons two therapeutic candidates, triggering Wall Street ...
RBC Capital analyst Brian Abrahams downgraded IGM Biosciences (IGMS) to Sector Perform from Outperform with a price target of $1.50, down from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback